

Supplementary Table 2. Second-line treatment strategies

Second-line treatment		1980-1989	1990-1999	2000-2009	2010-2017	Total
No treatment	n	2	2	6	5	15
	%	4%	2%	6%	10%	4%
R-CHOP/R-CVP	n	1	4	15	5	25
	%	2%	3%	14%	10%	7%
Single-agent rituximab	n	3	8	25	2	38
	%	5%	6%	23%	4%	11%
Benda/Fluda-based (+/- R)	n	1	34	19	15	69
	%	2%	26%	17%	29%	20%
Other chemo regimens	n	25	40	17	16	98
	%	45%	31%	16%	31%	28%
Chlorambucil and other agents	n	23	15	1	0	39
	%	41%	12%	1%	0%	11%
ASCT	n	1	23	22	7	53
	%	2%	18%	20%	14%	15%
Allo-SCT	n	0	3	4	1	8
	%	0%	2%	4%	2%	2%

CVP, cyclophosphamide, vincristine, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; Benda, bendamustine; Fluda, fludarabine; chemo, chemotherapy; ASCT, autologous stem cell transplantation; Allo-SCT, allogeneic stem cell transplantation.